Answers are grounded in this paper and cite their sources.
Asymptomatic pre-heart failure (stage B) is highly prevalent, particularly in the elderly, men, and those with hypertension, and carries a notable risk of progression to symptomatic HF and mortality.
A systematic review was conducted between 01 January 2010 and 12 March 2020 (PROSPERO: CRD42020176141). Data of interest included prevalence, disease progression, and mortality rates. In total, 1030 sources were identified, of which, 12 reported on pre-HF (using the ACC/AHA definition for stage B HF) and were eligible. Prevalence estimates of pre-HF ranged from 11 to 42.7% (10 sources) with higher estimates found in the elderly, in patients with hypertension, and in men. Three studies reported on disease progression with follow-up ranging from 13 months to 7 years. The incidence of symptomatic HF (HF/advanced HF) ranged from 0.63 to 9.8%, and all-cause mortality from 1.6 to 5.4%. Further research is required to investigate whether early detection and intervention can slow or stop the progression from asymptomatic to symptomatic HF.
No takes yet. Share an insight, caveat, or question.
Bergamasco et al. (2022) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: